GlassScriptPhysician profile
Robert Emery Delphia
NPI 1407896954
$1,678.18
in general payments reported to CMS, 2019-2025
13 companies · $559 in 2025
The $559 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $280 · 2021: $53.15 · 2022: $65.10 · 2023: $76.79 · 2024: $176 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $383.35 | 2019-2025 | Repatha, Repatha |
| Heartflow, INC. | $292.44 | 2025 | |
| Novartis Pharmaceuticals Corporation | $263.34 | 2019-2023 | |
| Penumbra, INC. | $160.34 | 2025 | Ruby Coil |
| Astrazeneca Pharmaceuticals LP | $147.62 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $122.54 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $79.78 | 2019-2021 | |
| Abbott Laboratories | $64.01 | 2022-2024 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit |
| Atricure, INC. | $58.07 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Pfizer INC. | $51.54 | 2019-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $18.99 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.88 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.28 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Delphia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.